MLYS - CIK 0001933414
The table below shows Mineralys Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $24.36M | $31.45M | $38.28M | $37.88M | $53.98M | $39.27M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $20.98M |
| $9.68M |
| $8.47M |
| $6.57M |
| $6.12M |
| $5.89M |
| Operating income | -$45.34M | -$41.13M | -$46.75M | -$44.45M | -$60.11M | -$45.17M |
| Income tax | - | - | - | - | - | - |
| Net income | -$39.34M | -$36.93M | -$43.27M | -$42.21M | -$56.34M | -$41.01M |
| EPS (diluted) | -$0.47 | -$0.52 | -$0.66 | -$0.79 | -$1.13 | -$0.83 |